HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seeman, P.J.V. Articles by Rolfs, A. Search for Related Content PubMed PubMed Citation Articles by Seeman, P.J.V. Articles by Rolfs, A.

Two new missense mutations in a non-Jewish Caucasian family with type 3 Gaucher disease

From the AG Molekulare Neurobiologie am Institut fur Neuropsychopharmakologie, Freie Universitat Berlin (Drs. Seeman, Finckh, and Rolfs), Neurologische Abteilung (Drs. Hoppner and Rolfs), Innere Abteilung (Drs. Lakner and Liebisch), and Radiologische Klinik der Universitat Rostock (Dr. Grau), Germany.
Presented in part and in preliminary form at the 27th Annual Meeting of the European Society of Human Genetics, Berlin, May 1995.
Received May 19, 1995. Accepted in final form August 6, 1995.
Address correspondence and reprint requests to Dr. Arndt Rolfs, University of Rostock, Department of Neurology, POB 100 888, Gehlsheimerstr. 20, 18055 Rostock, Germany.

Gaucher disease is an autosomal recessive, lysosomal storage disease caused by a deficiency of the enzyme glucocerebrosidase.The prevalence of this disorder differs significantly among various populations and is highest in some Jewish populations. More than 35 disease-producing mutations of the gene have been reported. The change of the amino acid leucine at position 444 to proline (sup 444 Leu right arrow Pro) is the most common mutation in non-Jewish populations, and a second mutation at amino acid 370 (sup 370 Asn right arrow Ser) is the most common one in Jewish populations. However, most of the mutations have been reported in very few cases or even in only one pedigree. We performed a direct DNA sequencing analysis of the complete functional glucocerebrosidase gene in a 22-year-old neuronopathic non-Jewish patient with Gaucher disease type 3 with myoclonic epilepsy and slight mental disturbances and in most members of his family. After selective amplification of the complete coding region of the patient's functional glucocerebrosidase gene, we identified two hitherto unreported mutations in exon 9 (genomic nucleotide⁵²²⁴ G right arrow C;⁴¹⁷ Val right arrow Leu) and in exon 11 (genomic nucleotide⁶⁶⁶⁸ C right arrow T;⁵¹⁰ Thr right arrow Ile). Each parent showed one of these mutations. Once we sequenced the complete active gene, we could rule out the existence of further mutations. Data that show that in about 15 to 25% of non-Jewish patients with Gaucher disease no mutations within the glucocerebrosidase gene are found may be due to inappropriate screening methods, mostly used for the genotyping. Until we have precise information about the frequency and distribution of single-point mutations in patients with Gaucher disease, it is necessary to analyze the complete glucocerebrosidase gene.

NEUROLOGY 1996;46: 1102-1107

This article has been cited by other articles:

				B. Liou, A. Kazimierczuk, M. Zhang, C. R. Scott, R. S. Hegde, and G. A. Grabowski Analyses of Variant Acid beta-Glucosidases: EFFECTS OF GAUCHER DISEASE MUTATIONS J. Biol. Chem., February 17, 2006; 281(7): 4242 - 4253. [Abstract] [Full Text] [PDF]

				L. Premkumar, A. R. Sawkar, S. Boldin-Adamsky, L. Toker, I. Silman, J. W. Kelly, A. H. Futerman, and J. L. Sussman X-ray Structure of Human Acid-{beta}-Glucosidase Covalently Bound to Conduritol-B-Epoxide: IMPLICATIONS FOR GAUCHER DISEASE J. Biol. Chem., June 24, 2005; 280(25): 23815 - 23819. [Abstract] [Full Text] [PDF]